Ann Malar Res | Volume 1, Issue 1 | Research Article | Open Access
Bastidas G*
Department of Public Health, University of Carabobo, Venezuela
*Correspondance to: Bastidas G
Fulltext PDFPlasmodium vivax malaria is an important public health problem in Venezuela where the therapeutic regimen administers primaquine as the only drug available to prevent recurrence of P. vivax malaria. However, Primaquine is an oxidative drug that can cause hemolysis in subjects deficient in the enzyme Glucose-6-Phosphate Dehydrogenase. The objective of this paper is to show concisely what was done and found about this enzyme defect in Venezuela. Based on the review of the scientific literature of virtual data (Bireme/OPS, Medline, PudMed, Scielo) from descriptors or related keywords, the objective of this research was achieved. The information found is located in three chapters: Malaria as a public health problem; treatment of P. vivax malaria and G6PD deficiency; and G6PD deficiency in Venezuela. It is concluded that the researchers have advanced progressively and firmly in obtaining information about G6PD deficiency in Venezuela, a country considered endemic for P. vivax malaria, in order to provide key information for the treatment of such an important health problem.
Malaria; Plasmodium vivax; Primaquine; Hemolytic anemia; G6PD
Bastidas G. Malaria by Plasmodium vivax and Deficiency of Glucose6-phosphate Dehydrogenase: The Venezuela Case. Ann Malar Res. 2018; 1(1): 1001.